MEAK - KCNC1 - Arg320His

07/26/2024

We had great time meeting up with another MEAK warrior in Philadelphia.

07/23/2024

Charles Large, Autifony CEO, talks to BiotechTV’s Amy Brown about progress in ion channel drug discovery and exciting hopes for novel treatments for rare paediatric epilepsy disorders.

Charles Large, Autifony CEO, talks to BiotechTV’s Amy Brown about progress in ion channel drug discovery and exciting hopes for novel treatments for rare paediatric epilepsy disorders.22 July 2024 Share this entryShare on Twitter https://autifony.com/wp-content/uploads/2022/05/autifony_therapeutic...

07/22/2024

MEAK warriors meeting up for the first time in upstate New York!

03/26/2024

03/05/2024

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10897601/

11/15/2023

https://www.fiercebiotech.com/biotech/jazz-locks-arms-gsk-spinout-autifony-putting-771m-form-neuroscience-discovery-pact

GSK spinout Autifony Therapeutics has

05/24/2023

Interesting publication related to MEAK and KCNC1 related variants.

Variable phenotypes, including developmental encephalopathy with (DEE) or without (DE) seizures and myoclonic epilepsy and ataxia due to potassium channel mutation (MEAK), are caused by pathogenetic variants in KCNC1, encoding for Kv3.1 channel subunits. In vitro, channels carrying most KCNC1 pathog...

04/14/2023

https://chop.donordrive.com/index.cfm?fuseaction=donorDrive.personalCampaign&participantID=91139

Help to support me and Children's Hospital of Philadelphia Foundation through my fundraising page!

02/15/2023

https://walktoendepilepsy.org/?utm_campaign=w2ee&utm_content=1673991739&utm_medium=social&utm_source=twitter

Leading the fight to overcome the challenges of living with epilepsy and to accelerate therapies to stop seizures, find cures, and save lives.